- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01976559
Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recently, astronauts in long-duration spaceflight have been found to have a syndrome consisting of swelling of the optic nerve, impaired vision, and elevated cerebrospinal fluid pressure (also known as intracranial pressure [ICP]) via lumbar puncture (LP), which is similar to the syndrome of idiopathic intracranial hypertension (IIH). In astronauts, this syndrome is called Visual Impairment/Intracranial Pressure (VIIP). It is not possible to perform an LP on astronauts in space. Noninvasive methods of estimating ICP exist but have not been tested against continuous ICP methods in a patient cohort that is physiologically similar to that of astronauts.
The primary objective of this study is to determine the validity, reliability, accuracy, and precision of two noninvasive methods of ICP measurement (tympanic membrane displacement (TMD, Marchbanks Measurements Systems, UK) and distortion product otoacoustic emissions (DPOAE) in comparison to a reference standard, invasive ICP measurement, in human subjects undergoing diagnostic cerebrospinal fluid (CSF) infusion testing.
The two noninvasive methods are based on the responses of the inner ear and middle ear to changes in ICP. The first method is TMD, which measures tiny movements of the ear drum, and the second is DPOAE, which is routinely used for newborn hearing screening.
Adults with hydrocephalus, shunt malfunction, or other disorders of CSF circulation who have been recommended on the basis of standard clinical criteria to have CSF infusion testing are eligible.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Umea, Sweden
- University of Umea Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of suspected hydrocephalus or shunt malfunction
- CSF infusion testing has been recommended on the basis of standard clinical criteria
- Capable of providing valid signed informed consent
- Normal middle-ear function as determined by tympanometry
- DPOAE meet criteria that are required for the research
- Acoustic stapedial reflex meets criteria that are required for the research
- Subject is willing and able to participate in the study
Exclusion Criteria:
- Subject is pregnant
- Subject lacks decision-making capacity
- Subject is unwilling to participate in the study
- Prior middle-ear disease or surgery, with the exception of tympanostomy tubes that have been removed and are healed
- Participating in the study would significantly delay or interfere with the subject's healthcare
- Subject has excess ear wax that cannot be removed safely and could potentially be pushed onto the ear drum by insertion of the ear plugs needed for the testing
- The TMD or DPOAE do not respond to a change in posture from lying flat to standing up, which means that the anatomic connection between the inner ear and the CSF is absent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hydrocephalus / Shunt Malfunction
Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing.
The interventions include tympanic membrane displacement (TMD) and DPOAE.
|
DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones.
DPOAE measurements will be made for 13 tones.
The total measurement time for each condition is 2-4 minutes.
Other Names:
The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst. For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Noninvasive ICP
Time Frame: Day 1 (Concurrent with CSF infusion testing)
|
Bland-Altman analysis: the difference between the noninvasive ICP and the invasive ICP is plotted against the mean of both the noninvasive and invasive ICP at each ICP level
|
Day 1 (Concurrent with CSF infusion testing)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael A Williams, MD, Sinai Hospital of Baltimore / LifeBridge Health
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 1964
- SMST02802 (Other Grant/Funding Number: National Space Biomedical Research Institute SMST02802)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hydrocephalus
-
University of Kansas Medical CenterWithdrawnLow Pressure Hydrocephalus
-
Göteborg UniversityDepartment of Neurological Surgery, Sahlgrenska University Hospital; Hydrocephalus... and other collaboratorsNot yet recruitingNormal Pressure Hydrocephalus | Normal Pressure Hydrocephalus Patients
-
Mayo ClinicTerminatedNormal Pressure Hydrocephalus PatientsUnited States
-
Umeå UniversityCompleted
-
Umeå UniversityCompletedIdiopathic Normal Pressure Hydrocephalus
-
University Hospital, Basel, SwitzerlandRecruitingIdiopathic Normal Pressure Hydrocephalus (INPH)Switzerland
-
DeepsonbioRecruitingIdiopathic Normal Pressure Hydrocephalus (iNPH)Korea, Republic of
-
Uppsala University HospitalUppsala University; Swedish Society for Medical ResearchCompletedIdiopathic Normal Pressure Hydrocephalus (INPH)Sweden
-
Johns Hopkins UniversityUniversity of Utah; Integra LifeSciences CorporationCompletedIdiopathic Normal Pressure Hydrocephalus (INPH)United States, Canada, Sweden
-
Dokuz Eylul UniversityRecruitingNPH (Normal Pressure Hydrocephalus)Turkey
Clinical Trials on DPOAE
-
Ondokuz Mayıs UniversityCompletedMultiple Sclerosis | Obesity | Hearing LossTurkey
-
Gateway Biotechnology, Inc.University of Pittsburgh; National Institute on Deafness and Other Communication...Withdrawn
-
Memorial Sloan Kettering Cancer CenterCompletedHearing Loss | Intraocular RetinoblastomaUnited States
-
LifeBridge HealthTerminatedIdiopathic Intracranial Hypertension | Pseudotumor Cerebri | HydrocephalusUnited States
-
The University of Texas Health Science Center at...National Institute of Mental Health (NIMH); Hearing Center of ExcellenceCompletedPosttraumatic Stress Disorder | TinnitusUnited States